Cabell Christopher has filed 4 insider transactions across 1 company since February 2025.
Most recent transaction: a disposition of 338282 shares of Inhibikase Therapeutics, Inc. ($IKT) on February 21, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 21, 2026 | Inhibikase Therapeutics, Inc. | $IKT | Cabell Christopher | President & Head of R&D | D | Common Stock | 338282 | $0.00 | 676,564.0000 | 90,050,973 | 33.33% | 0.38% |
| Jan. 5, 2026 | Inhibikase Therapeutics, Inc. | $IKT | Cabell Christopher | President & Head of R&D | A | Stock Option (Right to Buy) | 900117 | $0.00 | 900,117.0000 | 90,050,973 | 9999.99% | 1.00% |
| Feb. 21, 2025 | Inhibikase Therapeutics, Inc. | $IKT | Cabell Christopher | President & Head of R&D | A | Stock Option (Right to Buy) | 1100705 | $0.00 | 1,100,705.0000 | 23,712,220 | 9999.99% | 4.64% |
| Feb. 21, 2025 | Inhibikase Therapeutics, Inc. | $IKT | Cabell Christopher | President & Head of R&D | A | Stock Option (Right to Buy) | 1100705 | $0.00 | 1,100,705.0000 | 23,712,220 | 9999.99% | 4.64% |